Rapid Micro Biosystems (NASDAQ:RPID – Get Free Report) and Icon (NASDAQ:ICLR – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.
Insider and Institutional Ownership
52.6% of Rapid Micro Biosystems shares are owned by institutional investors. Comparatively, 95.6% of Icon shares are owned by institutional investors. 12.7% of Rapid Micro Biosystems shares are owned by company insiders. Comparatively, 44.0% of Icon shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Rapid Micro Biosystems and Icon”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rapid Micro Biosystems | $33.59 million | 1.10 | -$47.12 million | ($1.12) | -0.66 |
| Icon | $8.25 billion | 1.81 | $229.34 million | $5.81 | 33.57 |
Icon has higher revenue and earnings than Rapid Micro Biosystems. Rapid Micro Biosystems is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Rapid Micro Biosystems has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, Icon has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent recommendations for Rapid Micro Biosystems and Icon, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rapid Micro Biosystems | 1 | 2 | 1 | 0 | 2.00 |
| Icon | 1 | 9 | 9 | 1 | 2.50 |
Rapid Micro Biosystems currently has a consensus price target of $1.81, indicating a potential upside of 146.00%. Icon has a consensus price target of $213.76, indicating a potential upside of 9.61%. Given Rapid Micro Biosystems’ higher probable upside, equities analysts clearly believe Rapid Micro Biosystems is more favorable than Icon.
Profitability
This table compares Rapid Micro Biosystems and Icon’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rapid Micro Biosystems | -138.24% | -211.25% | -77.03% |
| Icon | 5.45% | 7.73% | 4.39% |
Summary
Icon beats Rapid Micro Biosystems on 13 of the 15 factors compared between the two stocks.
About Rapid Micro Biosystems
Rapid Micro Biosystems develops automated microbial detection systems for pharmaceutical, biotechnology and other life sciences manufacturers. Its products are designed to support quality-control testing by identifying and measuring microbial growth in manufacturing environments and products. The company’s Growth Direct platform combines laboratory instruments, consumables and software to automate microbial testing. Its applications include sterility testing, bioburden testing and environmental monitoring, helping manufacturers assess contamination during production.
About Icon
ICON plc is a global contract research organization (CRO) that provides outsourced development services to pharmaceutical, biotechnology, medical device and government organizations. Its work supports the development of medicines and other healthcare products from early research through clinical trials and regulatory submission. The company’s services include clinical trial design and management, data management and biostatistics, regulatory support, laboratory services, medical imaging and patient recruitment.
Receive News & Ratings for Rapid Micro Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapid Micro Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.
